<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="e2aa1642-d262-4520-bc6a-9fd3ad795677"><labelDrug name="Norpace"><Normalization><mmtx cui="C0701129" preferredWord="Norpace" semType="phsu, orch"/></Normalization></labelDrug><generic name="disopyramide phosphate"/><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.1" text="Drug Label for drug brand Norpace, containing disopyramide phosphate." type="negative"><entity charOffset="46:68" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.1.e.0" text="disopyramide phosphate" type="Biomedical_Entity"><Normalization><mmtx cui="C0700534" phraseText="disopyramide phosphate." preferredWord="Disopyramide Phosphate" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><entity charOffset="0:19" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.1.e.1" text="drug drug" type="Biomedical_Entity"><Normalization><mmtx cui="C0013231" phraseText="Drug Label for drug brand Norpace," preferredWord="Drugs, Non-Prescription" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="26:33" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.1.e.2" text="norpace" type="Biomedical_Entity"><Normalization><mmtx cui="C0701129" phraseText="Drug Label for drug brand Norpace," preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.1.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.1.e.0"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.1.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.1.e.0"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.1.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.1.e.2"/></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.6" text="In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multi-center, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had had a myocardial infarction more than 6 days but less than 2 years previously, an excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3.0%). " type="negative"><entity charOffset="412:421" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.6.e.0" text="encainide" type="Biomedical_Entity"><Normalization><mmtx cui="C0085251" phraseText="treated with encainide" preferredWord="Encainide" semType="phsu, orch"/><RxNorm RxCui="281189"/></Normalization></entity><entity charOffset="425:435" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.6.e.1" text="flecainide" type="Biomedical_Entity"><Normalization><mmtx cui="C0016229" phraseText="flecainide" preferredWord="Flecainide" semType="phsu, orch"/><RxNorm RxCui="4441"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.6.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.6.e.1"/></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.7" text="The average duration of treatment with encainide or flecainide in this study was 10 months." type="negative"><entity charOffset="39:48" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.7.e.0" text="encainide" type="Biomedical_Entity"><Normalization><mmtx cui="C0085251" phraseText="with encainide" preferredWord="Encainide" semType="phsu, orch"/><RxNorm RxCui="281189"/></Normalization></entity><entity charOffset="52:62" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.7.e.1" text="flecainide" type="Biomedical_Entity"><Normalization><mmtx cui="C0016229" phraseText="flecainide in this study" preferredWord="Flecainide" semType="phsu, orch"/><RxNorm RxCui="4441"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.7.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.7.e.1"/></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9" text="Considering the known proarrhythmic properties of Norpace or Norpace CR and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of Norpace or Norpace CR as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias." type="negative"><entity charOffset="61:68" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.0" text="norpace" type="Biomedical_Entity"><Normalization><mmtx cui="C0701129" phraseText="Norpace CR" preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><entity charOffset="126:145" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.1" text="antiarrhythmic drug" type="Biomedical_Entity"><Normalization><mmtx cui="C0003195" phraseText="for any antiarrhythmic drug" preferredWord="Anti-Arrhythmia Agents" semType="phsu"/><RxNorm RxCui="883"/></Normalization></entity><entity charOffset="207:214" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.2" text="norpace" type="Biomedical_Entity"><Normalization><mmtx cui="C0701129" phraseText="the use of Norpace" preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><entity charOffset="246:267" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.3" text="antiarrhythmic agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0003195" phraseText="other antiarrhythmic agents" preferredWord="Anti-Arrhythmia Agents" semType="phsu"/><RxNorm RxCui="883"/></Normalization></entity><entity charOffset="218:225" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.4" text="norpace" type="Biomedical_Entity"><Normalization><mmtx cui="C0701129" phraseText="Norpace CR" preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><entity charOffset="50:57" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.5" text="norpace" type="Biomedical_Entity"><Normalization><mmtx cui="C0701129" phraseText="the known proarrhythmic properties of Norpace" preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.2"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.4"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.4" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.9.e.3"/></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.22" text="As with other Type 1A antiarrhythmics, disopyramide phosphate has been associated with torsade de pointes." type="negative"><entity charOffset="39:61" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.22.e.0" text="disopyramide phosphate" type="Biomedical_Entity"><Normalization><mmtx cui="C0700534" phraseText="disopyramide phosphate" preferredWord="Disopyramide Phosphate" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><entity charOffset="22:37" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.22.e.1" text="antiarrhythmics" type="Biomedical_Entity"><Normalization><mmtx cui="C0003195" phraseText="As with other Type 1A antiarrhythmics," preferredWord="Anti-Arrhythmia Agents" semType="phsu"/><RxNorm RxCui="883"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.22.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.22.e.0"/></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.25" text="In rare instances significant lowering of blood-glucose values has been reported during Norpace administration. " type="negative"><entity charOffset="88:95" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.25.e.0" text="norpace" type="Biomedical_Entity"><Normalization><mmtx cui="C0701129" phraseText="reported during Norpace administration." preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><entity charOffset="48:55" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.25.e.1" text="glucose" type="Biomedical_Entity"><Normalization><mmtx cui="C0017725" phraseText="of blood-glucose values" preferredWord="Glucose" semType="bacs, phsu, carb"/><RxNorm RxCui="4850"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.25.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.25.e.0"/></sentence><sentence biomedicalEntities="3" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26" lineNumber="36" text="The physician should be alert to this possibility, especially in patients with congestive heart failure, chronic malnutrition, hepatic, renal or other diseases, or drugs (e.g., beta-adrenoceptor blockers, alcohol) which could compromise preservation of the normal glucoregulatory mechanisms in the absence of food. " type="irregular"><anaphoraRelation><antecedentSentence ID="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.25" Text="In rare instances significant lowering of blood-glucose values has been reported during Norpace administration. "/><anaphoraEntity charOffset="38:49" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26.e.7" text="possibility" type="Expression"/><antecedentEntity charOffset="30:62" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.25.e.0" text="lowering of blood-glucose values" type="SPAN"/></anaphoraRelation><entity charOffset="177:203" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26.e.0" text="beta-adrenoceptor blockers" type="Drug_Class"><Normalization><mmtx cui="C0001645" phraseText="beta-adrenoceptor blockers," preferredWord="Adrenergic beta-Antagonists" semType="phsu"/><RxNorm RxCui="370"/></Normalization></entity><entity charOffset="205:212" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26.e.1" text="alcohol" type="Substance"><Normalization><mmtx cui="C0001975" phraseText="alcohol" preferredWord="Alcohols" semType="phsu, orch"/><RxNorm RxCui="448"/></Normalization></entity><entity charOffset="164:169|214:313" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26.e.2" text="drugs which could compromise preservation of the normal glucoregulatory mechanisms in the absence of food" type="Drug_Class"><Normalization><mmtx cui="C0013227" phraseText="drugs" preferredWord="Pharmaceutical Preparations" semType="phsu"/><mmtx cui="C0001645" phraseText="beta-adrenoceptor blockers," preferredWord="Adrenergic beta-Antagonists" semType="phsu"/><mmtx cui="C0001975" phraseText="alcohol" preferredWord="Alcohols" semType="phsu, orch"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="38:49" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26.e.5" text="possibility" type="Specific_Interaction"/><classClassMembership drugClass="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26.e.0"/><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26.ddi.1"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26.e.5"><relations><relation type="hasPrecipitant"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26.e.2"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.25" text="In rare instances significant lowering of blood-glucose values has been reported during Norpace administration. "><entity charOffset="88:95" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.25.e.1" text="Norpace" type="Drug"><Normalization><mmtx cui="C0701129" phraseText="reported during Norpace administration." preferredWord="Norpace" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26.e.2"/></sentence><sentence biomedicalEntities="0" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.27" lineNumber="36" text="In these patients the blood-glucose levels should be carefully followed." type="irregular"><entity charOffset="63:71" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.27.e.0" text="followed" type="Caution_Interaction"/><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.27.ddi.1"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.27.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26" text="The physician should be alert to this possibility, especially in patients with congestive heart failure, chronic malnutrition, hepatic, renal or other diseases, or drugs (e.g., beta-adrenoceptor blockers, alcohol) which could compromise preservation of the normal glucoregulatory mechanisms in the absence of food. "><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26.e.2"/></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.25" text="In rare instances significant lowering of blood-glucose values has been reported during Norpace administration. "><entity charOffset="88:95" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.25.e.1" text="Norpace" type="Drug"><Normalization><mmtx cui="C0701129" phraseText="reported during Norpace administration." preferredWord="Norpace" semType="phsu, orch"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.26" text="The physician should be alert to this possibility, especially in patients with congestive heart failure, chronic malnutrition, hepatic, renal or other diseases, or drugs (e.g., beta-adrenoceptor blockers, alcohol) which could compromise preservation of the normal glucoregulatory mechanisms in the absence of food. "/></relation></relations></interaction></drugInteraction></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29" text="The concomitant use of Norpace or Norpace CR with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening arrhythmias who are demonstrably unresponsive to single-agent antiarrhythmic therapy. " type="negative"><entity charOffset="131:146" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.0" text="antiarrhythmics" type="Biomedical_Entity"><Normalization><mmtx cui="C0003195" phraseText="Type 1C antiarrhythmics" preferredWord="Anti-Arrhythmia Agents" semType="phsu"/><RxNorm RxCui="883"/></Normalization></entity><entity charOffset="167:177" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.1" text="flecainide" type="Biomedical_Entity"><Normalization><mmtx cui="C0016229" phraseText="flecainide" preferredWord="Flecainide" semType="phsu, orch"/><RxNorm RxCui="4441"/></Normalization></entity><entity charOffset="23:30" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.2" text="norpace" type="Biomedical_Entity"><Normalization><mmtx cui="C0701129" phraseText="The concomitant use of Norpace" preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><entity charOffset="202:213" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.3" text="propranolol" type="Biomedical_Entity"><Normalization><mmtx cui="C0033497" phraseText="propranolol" preferredWord="Propranolol" semType="phsu, orch"/><RxNorm RxCui="82084"/></Normalization></entity><entity charOffset="64:85" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.4" text="antiarrhythmic agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0003195" phraseText="Norpace CR with other Type 1A antiarrhythmic agents" preferredWord="Anti-Arrhythmia Agents" semType="phsu"/><RxNorm RxCui="883"/></Normalization></entity><entity charOffset="34:41" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.5" text="norpace" type="Biomedical_Entity"><Normalization><mmtx cui="C0701129" phraseText="Norpace CR with other Type 1A antiarrhythmic agents" preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><entity charOffset="324:344" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.6" text="agent antiarrhythmic" type="Biomedical_Entity"><Normalization><mmtx cui="C0003195" phraseText="demonstrably unresponsive to single-agent antiarrhythmic therapy." preferredWord="Anti-Arrhythmia Agents" semType="phsu"/><RxNorm RxCui="126263"/></Normalization></entity><entity charOffset="181:192" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.7" text="propafenone" type="Biomedical_Entity"><Normalization><mmtx cui="C0033429" phraseText="propafenone" preferredWord="Propafenone" semType="phsu, orch"/><RxNorm RxCui="8754"/></Normalization></entity><entity charOffset="156:165" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.8" text="encainide" type="Biomedical_Entity"><Normalization><mmtx cui="C0085251" phraseText="such as encainide," preferredWord="Encainide" semType="phsu, orch"/><RxNorm RxCui="281189"/></Normalization></entity><entity charOffset="108:120" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.9" text="procainamide" type="Biomedical_Entity"><Normalization><mmtx cui="C0033216" phraseText="procainamide" preferredWord="Procainamide" semType="phsu, orch"/><RxNorm RxCui="155056"/></Normalization></entity><entity charOffset="95:104" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.10" text="quinidine" type="Biomedical_Entity"><Normalization><mmtx cui="C0034414" phraseText="such as quinidine" preferredWord="Quinidine" semType="phsu, orch"/><RxNorm RxCui="9068"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.0"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.0"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.7"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.8"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.9" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.0"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.10" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.0"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.4" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.6"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.7"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.8" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.9" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.10" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.4"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.6"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.7"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.8"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.9"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.10"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.4" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.3" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.6"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.7" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.8" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.9" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.10" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.4"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.4" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.7"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.4" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.8"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.4" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.9"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.4" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.10"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.6"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.7"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.8"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.9"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.10"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.7" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.6"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.8" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.6"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.9" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.6"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.10" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.6"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.8" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.7"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.9" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.7"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.10" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.7"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.9" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.8"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.10" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.8"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.10" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.9"/></sentence><sentence biomedicalEntities="0" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.30" lineNumber="40" text="Such use may produce serious negative inotropic effects, or may excessively prolong conduction. " type="irregular"><entity charOffset="29:55" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.30.e.0" text="negative inotropic effects" type="Specific_Interaction"/><entity charOffset="64:94" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.30.e.2" text="excessively prolong conduction" type="Specific_Interaction"/><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.30.ddi.1"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.30.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29" text="The concomitant use of Norpace or Norpace CR with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening arrhythmias who are demonstrably unresponsive to single-agent antiarrhythmic therapy. "><entity charOffset="123:146" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.7" text="Type 1C antiarrhythmics" type="Drug_Class"><Normalization><mmtx cui="C0003195" phraseText="Type 1C antiarrhythmics" preferredWord="Anti-Arrhythmia Agents" semType="phsu"/></Normalization></entity></ellipsisSentence></relation><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29" text="The concomitant use of Norpace or Norpace CR with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening arrhythmias who are demonstrably unresponsive to single-agent antiarrhythmic therapy. "><entity charOffset="56:85" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.2" text="Type 1A antiarrhythmic agents" type="Drug_Class"><Normalization><mmtx cui="C0003195" phraseText="Norpace CR with other Type 1A antiarrhythmic agents" preferredWord="Anti-Arrhythmia Agents" semType="phsu"/></Normalization></entity></ellipsisSentence></relation><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29" text="The concomitant use of Norpace or Norpace CR with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening arrhythmias who are demonstrably unresponsive to single-agent antiarrhythmic therapy. "><entity charOffset="202:213" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.11" text="propranolol" type="Drug"><Normalization><mmtx cui="C0033497" phraseText="propranolol" preferredWord="Propranolol" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29" text="The concomitant use of Norpace or Norpace CR with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening arrhythmias who are demonstrably unresponsive to single-agent antiarrhythmic therapy. "><entity charOffset="34:44" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.1" text="Norpace CR" type="Drug"><Normalization><mmtx cui="C0701129" phraseText="Norpace CR with other Type 1A antiarrhythmic agents" preferredWord="Norpace" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29" text="The concomitant use of Norpace or Norpace CR with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening arrhythmias who are demonstrably unresponsive to single-agent antiarrhythmic therapy. "><entity charOffset="23:30" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.0" text="Norpace" type="Drug"><Normalization><mmtx cui="C0701129" phraseText="The concomitant use of Norpace" preferredWord="Norpace" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.30.ddi.2"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.30.e.2"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29" text="The concomitant use of Norpace or Norpace CR with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening arrhythmias who are demonstrably unresponsive to single-agent antiarrhythmic therapy. "><entity charOffset="123:146" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.7" text="Type 1C antiarrhythmics" type="Drug_Class"><Normalization><mmtx cui="C0003195" phraseText="Type 1C antiarrhythmics" preferredWord="Anti-Arrhythmia Agents" semType="phsu"/></Normalization></entity></ellipsisSentence></relation><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29" text="The concomitant use of Norpace or Norpace CR with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening arrhythmias who are demonstrably unresponsive to single-agent antiarrhythmic therapy. "><entity charOffset="56:85" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.2" text="Type 1A antiarrhythmic agents" type="Drug_Class"><Normalization><mmtx cui="C0003195" phraseText="Norpace CR with other Type 1A antiarrhythmic agents" preferredWord="Anti-Arrhythmia Agents" semType="phsu"/></Normalization></entity></ellipsisSentence></relation><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29" text="The concomitant use of Norpace or Norpace CR with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening arrhythmias who are demonstrably unresponsive to single-agent antiarrhythmic therapy. "><entity charOffset="202:213" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.11" text="propranolol" type="Drug"><Normalization><mmtx cui="C0033497" phraseText="propranolol" preferredWord="Propranolol" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29" text="The concomitant use of Norpace or Norpace CR with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening arrhythmias who are demonstrably unresponsive to single-agent antiarrhythmic therapy. "><entity charOffset="34:44" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.1" text="Norpace CR" type="Drug"><Normalization><mmtx cui="C0701129" phraseText="Norpace CR with other Type 1A antiarrhythmic agents" preferredWord="Norpace" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29" text="The concomitant use of Norpace or Norpace CR with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening arrhythmias who are demonstrably unresponsive to single-agent antiarrhythmic therapy. "><entity charOffset="23:30" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.29.e.0" text="Norpace" type="Drug"><Normalization><mmtx cui="C0701129" phraseText="The concomitant use of Norpace" preferredWord="Norpace" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation></relations></interaction></drugInteraction></sentence><sentence biomedicalEntities="1" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.32" lineNumber="40" text="Patients receiving more than one antiarrhythmic drug must be carefully monitored." type="regular"><entity charOffset="71:80" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.32.e.0" text="monitored" type="Caution_Interaction"/><entity charOffset="33:52" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.32.e.2" text="antiarrhythmic drug" type="Drug_Class"><Normalization><mmtx cui="C0003195" phraseText="more than one antiarrhythmic drug" preferredWord="Anti-Arrhythmia Agents" semType="phsu"/><RxNorm RxCui="883"/></Normalization></entity><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.32.ddi.1"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.32.e.0"><relations><relation type="hasObject"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.32.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.32.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.32.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.32.e.2" trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.32.e.0" type="Caution_Interaction"/></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38" text="Because of its anticholinergic activity, disopyramide phosphate should not be used in patients with glaucoma, myasthenia gravis, or urinary retention unless adequate overriding measures are taken, these consist of the topical application of potent miotics (e.g., pilocarpine) for patients with glaucoma, and catheter drainage or operative relief for patients with urinary retention. " type="negative"><entity charOffset="15:30" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.0" text="anticholinergic" type="Biomedical_Entity"><Normalization><mmtx cui="C3537004" phraseText="Because of its anticholinergic activity," preferredWord="Anticholinergic [EPC]" semType="phsu"/><RxNorm RxCui="1437161"/></Normalization></entity><entity charOffset="263:274" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.1" text="pilocarpine" type="Biomedical_Entity"><Normalization><mmtx cui="C0031923" phraseText="pilocarpine" preferredWord="Pilocarpine" semType="phsu, orch"/><RxNorm RxCui="103244"/></Normalization></entity><entity charOffset="41:63" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.2" text="disopyramide phosphate" type="Biomedical_Entity"><Normalization><mmtx cui="C0700534" phraseText="disopyramide phosphate" preferredWord="Disopyramide Phosphate" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><entity charOffset="248:255" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.3" text="miotics" type="Biomedical_Entity"><Normalization><mmtx cui="C0026207" phraseText="consist of the topical application of potent miotics" preferredWord="Miotics" semType="phsu"/><RxNorm RxCui="6987"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.2"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.3" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.38.e.3"/></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.41" text="Disopyramide phosphate should be used with special care in patients with myasthenia gravis since its anticholinergic properties could precipitate a myasthenic crisis in such patients." type="negative"><entity charOffset="101:116" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.41.e.0" text="anticholinergic" type="Biomedical_Entity"><Normalization><mmtx cui="C3537004" phraseText="its anticholinergic properties" preferredWord="Anticholinergic [EPC]" semType="phsu"/><RxNorm RxCui="1437161"/></Normalization></entity><entity charOffset="0:22" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.41.e.1" text="disopyramide phosphate" type="Biomedical_Entity"><Normalization><mmtx cui="C0700534" phraseText="Disopyramide phosphate" preferredWord="Disopyramide Phosphate" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.41.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.41.e.0"/></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.64" text="Therefore, potassium abnormalities should be corrected before starting Norpace or Norpace CR therapy." type="negative"><entity charOffset="71:78" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.64.e.0" text="norpace" type="Biomedical_Entity"><Normalization><mmtx cui="C0701129" phraseText="corrected before starting Norpace" preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><entity charOffset="11:20" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.64.e.1" text="potassium" type="Biomedical_Entity"><Normalization><mmtx cui="C0597277" phraseText="potassium abnormalities" preferredWord="Potassium Ion" semType="phsu, elii"/><RxNorm RxCui="8588"/></Normalization></entity><entity charOffset="82:89" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.64.e.2" text="norpace" type="Biomedical_Entity"><Normalization><mmtx cui="C0701129" phraseText="Norpace CR therapy." preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.64.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.64.e.0"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.64.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.64.e.2"/></sentence><sentence biomedicalEntities="5" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66" lineNumber="85" text="If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur. " type="regular"><anaphoraRelation><anaphoraEntity charOffset="120:132" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.2" text="disopyramide" type="Drug"/><antecedentEntity charOffset="85-95" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.6" text="Norpace CR" type="Drug"/></anaphoraRelation><anaphoraRelation><anaphoraEntity charOffset="120:132" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.2" text="disopyramide" type="Drug"/><antecedentEntity charOffset="74-81" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.5" text="Norpace" type="Drug"/></anaphoraRelation><entity charOffset="97:116" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.0" text="lower plasma levels" type="Decrease_Interaction"/><entity charOffset="120:132" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.2" text="disopyramide" type="Drug"><Normalization><mmtx cui="C0012702" phraseText="plasma levels of disopyramide" preferredWord="Disopyramide" semType="phsu, orch"/><mmtx cui="C0012702" phraseText="plasma levels of disopyramide" preferredWord="Disopyramide" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><entity charOffset="22:45" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.3" text="hepatic enzyme inducers" type="Drug_Class"><Normalization><RxNorm RxCui="1023819"/></Normalization></entity><entity charOffset="3:12" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.4" text="phenytoin" type="Drug"><Normalization><mmtx cui="C0031507" phraseText="phenytoin" preferredWord="Phenytoin" semType="phsu, orch"/><RxNorm RxCui="8183"/></Normalization></entity><entity charOffset="74:81" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.5" text="Norpace" type="Drug"><Normalization><mmtx cui="C0701129" phraseText="concurrently with Norpace" preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><entity charOffset="85:95" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.6" text="Norpace CR" type="Drug"><Normalization><mmtx cui="C0701129" phraseText="Norpace CR," preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.ddi.1"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.3" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.2" trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.0" type="Decrease_Interaction"/><pair ddi="true" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.4" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.2" trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.0" type="Decrease_Interaction"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.4" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.3"/></sentence><sentence biomedicalEntities="1" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.67" lineNumber="85" text="Monitoring of disopyramide plasma levels is recommended in such concurrent use to avoid ineffective therapy. " type="irregular"><entity charOffset="0:10" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.67.e.0" text="Monitoring" type="Caution_Interaction"/><entity charOffset="14:26" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.67.e.2" text="disopyramide" type="Drug"><Normalization><mmtx cui="C0012702" phraseText="Monitoring of disopyramide plasma levels" preferredWord="Disopyramide" semType="phsu, orch"/><mmtx cui="C0012702" phraseText="Monitoring of disopyramide plasma levels" preferredWord="Disopyramide" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.67.ddi.1"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.67.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66" text="If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur. "><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.3"/></ellipsisSentence></relation><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66" text="If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur. "><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.66.e.4"/></ellipsisSentence></relation><relation type="hasObject"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.67.e.2"/></relation></relations></interaction></drugInteraction></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68" text="Other antiarrhythmic drugs (e.g., quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace. " type="negative"><entity charOffset="70:81" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.0" text="propranolol" type="Biomedical_Entity"><Normalization><mmtx cui="C0033497" phraseText="propranolol" preferredWord="Propranolol" semType="phsu, orch"/><RxNorm RxCui="82084"/></Normalization></entity><entity charOffset="129:136" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.1" text="norpace" type="Biomedical_Entity"><Normalization><mmtx cui="C0701129" phraseText="concurrently with Norpace." preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><entity charOffset="45:57" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.2" text="procainamide" type="Biomedical_Entity"><Normalization><mmtx cui="C0033216" phraseText="procainamide," preferredWord="Procainamide" semType="phsu, orch"/><RxNorm RxCui="155056"/></Normalization></entity><entity charOffset="34:43" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.3" text="quinidine" type="Biomedical_Entity"><Normalization><mmtx cui="C0034414" phraseText="quinidine," preferredWord="Quinidine" semType="phsu, orch"/><RxNorm RxCui="9068"/></Normalization></entity><entity charOffset="59:68" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.4" text="lidocaine" type="Biomedical_Entity"><Normalization><mmtx cui="C0023660" phraseText="lidocaine," preferredWord="Lidocaine" semType="phsu, orch"/><RxNorm RxCui="6387"/></Normalization></entity><entity charOffset="6:26" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.5" text="antiarrhythmic drugs" type="Biomedical_Entity"><Normalization><mmtx cui="C0003195" phraseText="Other antiarrhythmic drugs" preferredWord="Anti-Arrhythmia Agents" semType="phsu"/><RxNorm RxCui="883"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.0"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.3" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.0"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.4" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.0"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.0"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.3" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.4" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.3" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.2"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.4"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.2"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.3" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.4"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.3"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.4"/></sentence><sentence biomedicalEntities="0" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.69" lineNumber="85" text="Excessive widening of the QRS complex and/or prolongation of the Q-T interval may occur in these situations (see Warnings ). " type="irregular"><entity charOffset="0:37" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.69.e.0" text="Excessive widening of the QRS complex" type="Specific_Interaction"/><entity charOffset="45:77" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.69.e.2" text="prolongation of the Q-T interval" type="Specific_Interaction"/><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.69.ddi.1"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.69.e.0"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68" text="Other antiarrhythmic drugs (e.g., quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace. "><entity charOffset="6:26" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.0" text="antiarrhythmic drugs" type="Drug_Class"><Normalization><mmtx cui="C0003195" phraseText="Other antiarrhythmic drugs" preferredWord="Anti-Arrhythmia Agents" semType="phsu"/></Normalization></entity></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68" text="Other antiarrhythmic drugs (e.g., quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace. "><entity charOffset="129:136" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.5" text="Norpace" type="Drug"><Normalization><mmtx cui="C0701129" phraseText="concurrently with Norpace." preferredWord="Norpace" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.69.ddi.2"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.69.e.2"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68" text="Other antiarrhythmic drugs (e.g., quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace. "><entity charOffset="6:26" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.0" text="antiarrhythmic drugs" type="Drug_Class"><Normalization><mmtx cui="C0003195" phraseText="Other antiarrhythmic drugs" preferredWord="Anti-Arrhythmia Agents" semType="phsu"/></Normalization></entity></ellipsisSentence></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68" text="Other antiarrhythmic drugs (e.g., quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace. "><entity charOffset="129:136" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.68.e.5" text="Norpace" type="Drug"><Normalization><mmtx cui="C0701129" phraseText="concurrently with Norpace." preferredWord="Norpace" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation></relations></interaction></drugInteraction></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.70" text="In healthy subjects, no significant drug-drug interaction was observed when Norpace was coadministered with either propranolol or diazepam. " type="negative"><entity charOffset="130:138" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.70.e.0" text="diazepam" type="Biomedical_Entity"><Normalization><mmtx cui="C0012010" phraseText="diazepam." preferredWord="Diazepam" semType="phsu, orch"/><RxNorm RxCui="3322"/></Normalization></entity><entity charOffset="115:126" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.70.e.1" text="propranolol" type="Biomedical_Entity"><Normalization><mmtx cui="C0033497" phraseText="coadministered with either propranolol" preferredWord="Propranolol" semType="phsu, orch"/><RxNorm RxCui="82084"/></Normalization></entity><entity charOffset="76:83" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.70.e.2" text="norpace" type="Biomedical_Entity"><Normalization><mmtx cui="C0701129" phraseText="Norpace" preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.70.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.70.e.0"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.70.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.70.e.0"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.70.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.70.e.1"/></sentence><sentence biomedicalEntities="4" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71" lineNumber="85" text="Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels. " type="regular"><anaphoraRelation><anaphoraEntity charOffset="91:103" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.3" text="disopyramide" type="Drug"/><antecedentEntity charOffset="30-37" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.0" text="Norpace" type="Drug"/></anaphoraRelation><entity charOffset="30:37" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.0" text="Norpace" type="Drug"><Normalization><mmtx cui="C0701129" phraseText="Concomitant administration of Norpace" preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><entity charOffset="71:90|104:110" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.1" text="increases in plasma levels" type="Increase_Interaction"/><entity charOffset="91:103" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.3" text="disopyramide" type="Drug"><Normalization><mmtx cui="C0012702" phraseText="in plasma disopyramide levels" preferredWord="Disopyramide" semType="phsu, orch"/><mmtx cui="C0012702" phraseText="in plasma disopyramide levels" preferredWord="Disopyramide" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><entity charOffset="142:151" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.4" text="quinidine" type="Drug"><Normalization><mmtx cui="C0034414" phraseText="slight decreases in plasma quinidine levels." preferredWord="Quinidine" semType="phsu, orch"/><mmtx cui="C0034414" phraseText="slight decreases in plasma quinidine levels." preferredWord="Quinidine" semType="phsu, orch"/><RxNorm RxCui="9068"/></Normalization></entity><entity charOffset="122:141|152:158" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.6" text="decreases in plasma levels" type="Decrease_Interaction"/><entity charOffset="42:51" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.8" text="quinidine" type="Drug"><Normalization><mmtx cui="C0034414" phraseText="quinidine" preferredWord="Quinidine" semType="phsu, orch"/><RxNorm RxCui="9068"/></Normalization></entity><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.ddi.1"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.8"/></relation><relation type="hasObject"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.3"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.ddi.2"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.4"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.8" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.3" trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.1" type="Increase_Interaction"/><pair ddi="true" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.4" trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.71.e.6" type="Decrease_Interaction"/></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.72" text="Norpace does not increase serum digoxin levels." type="negative"><entity charOffset="0:7" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.72.e.0" text="norpace" type="Biomedical_Entity"><Normalization><mmtx cui="C0701129" phraseText="Norpace" preferredWord="Norpace" semType="phsu, orch"/><RxNorm RxCui="203631"/></Normalization></entity><entity charOffset="32:39" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.72.e.1" text="digoxin" type="Biomedical_Entity"><Normalization><mmtx cui="C0012265" phraseText="serum digoxin levels." preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.72.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.72.e.1"/></sentence><sentence biomedicalEntities="3" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73" lineNumber="86" text="Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration." type="regular"><anaphoraRelation><anaphoraEntity charOffset="95:107" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73.e.2" text="disopyramide" type="Drug"/><antecedentEntity charOffset="58-80" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73.e.4" text="disopyramide phosphate" type="Drug"/></anaphoraRelation><entity charOffset="115:141|145:160|164:175" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73.e.0" text="not be administered within hours before or hours after" type="Caution_Interaction"/><entity charOffset="95:107" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73.e.2" text="disopyramide" type="Drug"><Normalization><mmtx cui="C0012702" phraseText="disopyramide" preferredWord="Disopyramide" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><entity charOffset="176:185" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73.e.3" text="verapamil" type="Drug"><Normalization><mmtx cui="C0042523" phraseText="24 hours after verapamil administration." preferredWord="Verapamil" semType="phsu, orch"/><RxNorm RxCui="11170"/></Normalization></entity><entity charOffset="58:80" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73.e.4" text="disopyramide phosphate" type="Drug"><Normalization><mmtx cui="C0700534" phraseText="disopyramide phosphate" preferredWord="Disopyramide Phosphate" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73.ddi.1"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73.e.3" trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.73.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74" lineNumber="87" text="Although potent inhibitors of cytochrome P450 3A4 (e.g., ketoconazole) have not been studied clinically, in vitro studies have shown that erythromycin and oleandomycin inhibit the metabolism of disopyramide. " type="regular"><entity charOffset="138:150" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.0" text="erythromycin" type="Drug"><Normalization><mmtx cui="C0014806" phraseText="that erythromycin" preferredWord="Erythromycin" semType="orch, antb"/><RxNorm RxCui="4053"/></Normalization></entity><entity charOffset="155:167" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.1" text="oleandomycin" type="Drug"><Normalization><mmtx cui="C0028923" phraseText="oleandomycin" preferredWord="Oleandomycin" semType="carb, antb"/><RxNorm RxCui="7629"/></Normalization></entity><entity charOffset="168:190" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.2" text="inhibit the metabolism" type="Decrease_Interaction"><Normalization><mmtx cui="C0018790" phraseText="inhibit" preferredWord="Cardiac Arrest" semType="dsyn"/></Normalization></entity><entity charOffset="194:206" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.4" text="disopyramide" type="Drug"><Normalization><mmtx cui="C0012702" phraseText="the metabolism of disopyramide." preferredWord="Disopyramide" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><entity charOffset="105:121" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.5" text="in vitro studies" type="SPAN"/><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.ddi.1"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.2"><relations><relation type="hasEvidence"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.5"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.1"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.4" evidence="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.5" trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.2" type="Decrease_Interaction"/><pair ddi="true" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.4" evidence="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.5" trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.2" type="Decrease_Interaction"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.74.e.1"/></sentence><sentence biomedicalEntities="5" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75" lineNumber="87" text="Cases of life-threatening interactions have been reported for disopyramide when given with clarithromycin and erythromycin indicating that coadministration of disopyramide with inhibitors of cytochrome 3A4 could result in potentially fatal interaction." type="regular"><entity charOffset="9:38" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.0" text="life-threatening interactions" type="Caution_Interaction"/><entity charOffset="62:74" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.2" text="disopyramide" type="Drug"><Normalization><mmtx cui="C0012702" phraseText="reported for disopyramide" preferredWord="Disopyramide" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><entity charOffset="91:105" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.3" text="clarithromycin" type="Drug"><Normalization><mmtx cui="C0055856" phraseText="given with clarithromycin" preferredWord="Clarithromycin" semType="orch, antb"/><RxNorm RxCui="21212"/></Normalization></entity><entity charOffset="110:122" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.4" text="erythromycin" type="Drug"><Normalization><mmtx cui="C0014806" phraseText="erythromycin" preferredWord="Erythromycin" semType="orch, antb"/><RxNorm RxCui="4053"/></Normalization></entity><entity charOffset="159:171" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.5" text="disopyramide" type="Drug"><Normalization><mmtx cui="C0012702" phraseText="that coadministration of disopyramide" preferredWord="Disopyramide" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><entity charOffset="177:205" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.6" text="inhibitors of cytochrome 3A4" type="Drug_Class"><Normalization><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="222:251" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.7" text="potentially fatal interaction" type="Caution_Interaction"/><entity charOffset="9:25" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.9" text="life-threatening" type="SPAN"/><entity charOffset="222:239" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.10" text="potentially fatal" type="SPAN"/><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.ddi.1"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.0"><relations><relation type="hasSeverity"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.9"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.2"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.ddi.2"><interaction trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.7"><relations><relation type="hasSeverity"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.10"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.6"/></relation><relation type="hasObject"><entity id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.5"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.3" severity="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.9" trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.0" type="Caution_Interaction"/><pair ddi="true" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.4" severity="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.9" trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.0" type="Caution_Interaction"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.3" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.4"/><pair ddi="true" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.5" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.6" severity="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.10" trigger="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.75.e.7" type="Caution_Interaction"/></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.103" text="Because of its anticholinergic activity, disopyramide phosphate should not be used in patients with glaucoma, urinary retention, or benign prostatic hypertrophy (medical conditions commonly associated with the elderly) unless adequate overriding measures are taken (see Warnings: Anticholinergic Activity ). " type="negative"><entity charOffset="41:63" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.103.e.0" text="disopyramide phosphate" type="Biomedical_Entity"><Normalization><mmtx cui="C0700534" phraseText="disopyramide phosphate" preferredWord="Disopyramide Phosphate" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><entity charOffset="280:295" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.103.e.1" text="anticholinergic" type="Biomedical_Entity"><Normalization><mmtx cui="C0242896" phraseText="Anticholinergic Activity" preferredWord="Anticholinergic Agents" semType="phsu"/><RxNorm RxCui="1437161"/></Normalization></entity><entity charOffset="15:30" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.103.e.2" text="anticholinergic" type="Biomedical_Entity"><Normalization><mmtx cui="C3537004" phraseText="Because of its anticholinergic activity," preferredWord="Anticholinergic [EPC]" semType="phsu"/><RxNorm RxCui="1437161"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.103.e.0" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.103.e.1"/><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.103.e.2" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.103.e.0"/></sentence><sentence id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.104" text="In the event of increased anticholinergic side effects, plasma levels of disopyramide should be monitored and the dose of the drug adjusted accordingly. " type="negative"><entity charOffset="73:85" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.104.e.0" text="disopyramide" type="Biomedical_Entity"><Normalization><mmtx cui="C0012702" phraseText="plasma levels of disopyramide" preferredWord="Disopyramide" semType="phsu, orch"/><RxNorm RxCui="3541"/></Normalization></entity><entity charOffset="26:41" id="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.104.e.1" text="anticholinergic" type="Biomedical_Entity"><Normalization><mmtx cui="C3537004" phraseText="of increased anticholinergic side effects," preferredWord="Anticholinergic [EPC]" semType="phsu"/><RxNorm RxCui="1437161"/></Normalization></entity><pair ddi="false" e1="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.104.e.1" e2="Dailymed.e2aa1642-d262-4520-bc6a-9fd3ad795677.s.104.e.0"/></sentence><positiveExamples number="12"/><negativeExamples number="100"/></document>